The new anti-tuberculosis drug combination of bedaquiline, pretomanid and linezolid cures 90 percent of people with deadly drug-resistant TB if given for six months, researchers report in The New England Journal of Medicine.
Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.
The pharmaceutical industry should match its words with action on researching new antibiotics to address the threat posed by drug-resistant superbugs, a former UK government adviser said.
The spread of superbugs resistant to antimicrobial drugs shows no sign of slowing in Europe, health officials said, making food poisoning and other infections more difficult to treat.
RedHill Biopharma’s combination antibiotic Talicia met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.
Superbug infections resistant to multiple antibiotics kill around 33,000 people a year in Europe according to health experts, and the burden of these diseases is comparable to that of flu, tuberculosis and HIV combined.
An experimental GlaxoSmithKline vaccine could prevent tuberculosis developing in half of those who receive it, making the vaccine potentially the first new shot against the global killer in a century.
Two buildings at the Johns Hopkins Hospital in Baltimore were evacuated because people may have been exposed to tuberculosis, a hospital spokeswoman said.
Scientists seeking new ways to fight drug-resistant superbugs have mapped the genomes of more than 3,000 bacteria, including samples of a bug taken from Alexander Fleming’s nose and a dysentery-causing strain from a World War One soldier.
Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fueling the evolution of “superbugs” that do not respond to modern medicines, according to a new report.